TNO and FAST (Financiering en Acceleratie voor Therapieontwikkeling) have launched a strategic collaboration to accelerate the development of advanced therapies, including ATMPs, radiopharmaceuticals, treatments for rare diseases, infectious diseases, and drug repurposing.
Highlights:
Shared ambition to accelerate drug discovery by leveraging TNO’s innovation capabilities and deep collaborations with industry, government, and society.
Conny Helder (former Minister of Health) appointed as FAST’s new board chair, bringing strong leadership and signalling a strengthened link with TNO in publicly funded therapy programmes.
This partnership combines TNO’s technical and operational strength with FAST’s independent expert role, aiming to scale innovations that are both effective and affordable for patients.
Read more here
Leiden Bio Science Park welcomes Eli Lilly, strengthening The Netherlands' position in life sciences with a $3 billion facility. Eli Lilly and Company announced plans to build a...
From the Van Nelle Factory to BioPartner 5, from heritage to future, from start-up to innovative lab design agency. After an inspiring and innovative seven-year start at the...
Starting Friday, November 14 at 4:00 p.m., two temporary closures (in place for the duration of the Plesmanlaan project, until approximately Q3 2027) will be implemented for...